University Hospital Regensburg

 

University Hospital Regensburg

Franz-Josef-Strauss-Allee 11

93053 Regensburg

Germany

 

undefinedWebsite

 

 

 

Project leader

Prof. Dr. med. Matthias Edinger

Phone: +49 941 944-5580

Fax: +49 941 944-5581

undefinedE-Mail

 

Project staff

Christine Luginger

Technician

 

About the University Hospital Regensburg

The University Hospital Regensburg (UHREG) is one of the main academic hospitals in the state of Bavaria, Germany, with a medical research focus on

•    Transplantation Medicine
•    Immunopathology and Immunotherapy
•    Tumor Research

Prof. Matthias Edinger is a central protagonist for these research topics. He heads a clinical research group funded by the German Research Foundation (DFG) on the topic of “Cell-mediated regulation of auto- and allogeneic immune responses”, in which tolerance-promoting strategies are studied. He also leads a research team within the Bavarian Immunotherapy Network (BayImmuNet; www.bayimmunet.de) for the preparation and conduction of clinical trials on tolerance induction in stem cell transplantation. Furthermore, Prof. Edinger is scientific coordinator of a newly founded research institute (Regensburg Center for Interventional Immunology; www.rcii.de) that is focused on immunotherapies in autoimmunity, tumor and transplantation.

Allogeneic stem cell transplantation (SCT) and graft-versus-host-disease (GVHD) are central scientific and clinical topics of the Department of Internal Medicine III at the UHREG. A GVHD competence center supported by the José-Carreras-Foundation is established at the department. Apart from GVHD research, the center also offers clinical expertise in acute and chronic GVHD to external clinicians and patients are referred from other centers for second opinions and treatment optimization.

Matthias Edinger has a special interest in cellular immunoregulation and was among the first to describe the role of donor Treg cells in allogeneic SCT models during his postdoctoral stay at Stanford University. Since then he extensively described the phenotypic, functional, genetic and epigenetic characteristics of human Treg cells, developed GMP-compatible isolation strategies as well as optimized in vitro expansion conditions for human Treg cells and performed a phase I safety and feasibility trial testing freshly isolated donor Treg in SCT patients. He is director of the newly built GMP-facility at the University Hospital Regensburg (José-Carreras-Center for Somatic Cell Therapy; www.carreras-centrum.de) and implemented several new technologies for the generation of pure Treg cell products.

The TREGeneration partners

Search
Home
Menu
Top

Newsletter Subscription

Please fill in the information of your subscription.

 

You have already subscribed to Newsletter Recipients and wish to update or terminate your subscription? Click here!

News Section

TREGeneration team welcomes three external speakers Read more

Social Media

LinkedIn TREGeneration